Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Drug Profile

Aldoxorubicin - LadRx Corporation

Alternative Names: Aldoxorubicin hydrochloride; DOXO-EMCH; Doxorubicin-6-maleimidocaproyl hydrazone; INNO-206; Tumour-targeted doxorubicin conjugate - LadRx Corporation

Latest Information Update: 06 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KTB Tumorforschungs
  • Developer LadRx Corporation
  • Class Amines; Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Hexanoic acids; Hydrazines; Maleimides; Naphthacenes; Pyrroles; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Soft tissue sarcoma; Pancreatic cancer; Glioblastoma; Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Soft tissue sarcoma
  • Phase II Glioblastoma; Kaposi's sarcoma; Pancreatic cancer; Small cell lung cancer
  • Phase I/II Chondrosarcoma; Colorectal cancer; Osteosarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer

Most Recent Events

  • 03 Jun 2024 LadRx Corporation and XOMA amends the royalty purchase agreement to provide XOMA with a low-single-digit synthetic royalty from future out-license agreements related to aldoxorubicin
  • 03 Jun 2024 LadRx Corporation mutually terminates its aldoxorubicin licensing agreement with ImmunityBio and regains rights of aldoxorubicin
  • 22 May 2024 NantKwest terminates a phase I/II QUILT3-070 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (NCT03387098)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days